Purple Biotech Ltd. (PPBT) has released an update.
Purple Biotech Ltd., a biotech firm trading on NASDAQ/TASE as PPBT, has a strong financial standing with a cash balance of $15.3 million and is well-positioned for upcoming clinical trial readouts in 2024. The company focuses on developing innovative first-in-class drug candidates, including CM24 for pancreatic cancer, and boasts a pipeline of potential oncology therapies. With a cash runway into the first half of 2025, Purple Biotech is advancing its leading drug, CM24, potentially addressing the significant unmet needs in pancreatic ductal adenocarcinoma.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
